Trial reportPloS one2015
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03977363 (The Portuguese Survey on Anticoagulated Patients Register), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)
Who cites it
35 citing papers in PubMed, 66 citations in OpenAlex.
- Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis.Journal of the American Heart Association · 2025Trial
- Article
- Outcomes of non-valvular atrial fibrillation elderly patients maintained on VKAs' treatment compared to patients switched to DOACs: results from the STARTInternal and emergency medicine · 2026Article
- Characterization of anticoagulated patients in a Latin American country: indications, treatment patterns, and complications.Thrombosis journal · 2026Article
- Effectiveness of direct oral anticoagulants for all-cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry.European journal of clinical investigation · 2026Article
- Drug-related hepatotoxicity risk in elderly patients with atrial fibrillation: insights from the nationwide Italian START registry.Scientific reports · 2025Article
- Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Investigating interassay variability between direct oral anticoagulant calibrated anti-factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) trial.Research and practice in thrombosis and haemostasis · 2025Article
- Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users.Frontiers in endocrinology · 2025Article
- Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry.Journal of clinical medicine · 2024Article
- Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.Journal of clinical medicine · 2024Article
- DOACs use in extreme body-weighted patients: results from the prospective START-register.Internal and emergency medicine · 2023Observational
- Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes.Research and practice in thrombosis and haemostasis · 2023Article
- Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Clinical Outcomes after Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients with Anticoagulant versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study.Journal of cardiovascular development and disease · 2022Article
- Clinical Phenotypes of Atrial Fibrillation and Mortality Risk-A Cluster Analysis from the Nationwide Italian START Registry.Journal of personalized medicine · 2022Article
- Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register.Blood transfusion = Trasfusione del sangue · 2021Observational
- Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.Therapeutic advances in drug safety · 2021Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
START-Register--Survey on anTicoagulated pAtients RegisTer--is an independent, inception-cohort, observational, collaborative database aimed at recording prospectively the clinical history of adult patients starting anticoagulant treatment for any reason and using whatever drug. In this article we present the START-Register and give cross section baseline data focusing on non valvular atrial fibrillation (NVAF). Participants are asked to insert prospectively consecutive patients recorded as electronic file on the web-site of the registry. Required data are: demographic and clinical characteristics of patients, associated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treatment, expected therapeutic range (in cases of treatment with vitamin K antagonists -VKAs). The follow-up is carried out to record: quality of treatment (for patients on VKAs), bleeding complications, thrombotic events, and the onset of any type of associated disease. To date 5252 patients have been enrolled; 97.6% were on VKAs because direct oral anticoagulants (DOAC) have been available in Italy only recently. The median age was 74 years [interquartile range (IQR) 64-80]; males 53.7%. This analysis is focused on the 3209 (61.1%) NVAF patients. Mean CHADS2 score was 2.1 ± 1.1, CHADSVASc score was 3.1 ± 1.3;median age was 76 years (IQR 70-81); 168 patients (5.3%) had severe renal failure [Creatinine clearance (CrCl) <30 ml/min]. Moderate renal failure (CrCl 30-59 ml/min) was found in 1265 patients (39.5%). The analysis of the START-Register data shows that two-third of patients who started chronic anticoagulant treatment had NVAF, one-third of them was > 80 years with high prevalence of renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.